The World Market for Medicaments Containing Penicillins, Streptomycins, or Their Derivatives: A 2024 Global Trade Perspective
This report was created for strategic planners, international executives, and import/export managers who are concerned with the market for medicaments containing penicillins, streptomycins, or their derivatives excluding those in dosage form or retail packings. With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics that appear several years after the fact. Professor Philip M. Parker, the Chair Professor of Management Science at INSEAD, has developed a methodology, based on macroeconomic and trade models, to estimate the market for medicaments containing penicillins, streptomycins, or their derivatives excluding those in dosage form or retail packings for those countries serving the world market via exports or supplying from various countries via imports. He does so for the current year based on a variety of key historical indicators and econometric models.
'Medicaments containing penicillins, streptomycins, or their derivatives excluding those in dosage form or retail packings' as a category is defined in this report following the definition given by the United Nations Statistics Division Classification Registry using the Standard International Trade Classification, Revision 3 (SITC, Rev. 3). The SITC code that defines 'medicaments containing penicillins, streptomycins, or their derivatives excluding those in dosage form or retail packings' is 54211.
'Medicaments containing penicillins, streptomycins, or their derivatives excluding those in dosage form or retail packings' as a category is defined in this report following the definition given by the United Nations Statistics Division Classification Registry using the Standard International Trade Classification, Revision 3 (SITC, Rev. 3). The SITC code that defines 'medicaments containing penicillins, streptomycins, or their derivatives excluding those in dosage form or retail packings' is 54211.
1 METHODOLOGY
1.1 OUR APPROACH
2 THE WORLD MARKET
2.1 EXPORTS
2.1.1 THE WORLD MARKET: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS EXPORT SUPPLIES IN 2024
2.2 IMPORTS
2.2.1 THE WORLD MARKET: IMPORTED MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3 EXPORTS
3.1 AFRICA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.1.1 EXECUTIVE SUMMARY
3.1.2 EGYPT
3.1.3 KENYA
3.1.4 MOROCCO
3.1.5 SOUTH AFRICA
3.2 ASIA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.2.1 EXECUTIVE SUMMARY
3.2.2 CHINA
3.2.3 INDIA
3.2.4 INDONESIA
3.2.5 JAPAN
3.2.6 MALAYSIA
3.2.7 SINGAPORE
3.2.8 SOUTH KOREA
3.2.9 TAIWAN
3.2.10 THAILAND
3.3 EUROPE: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.3.1 EXECUTIVE SUMMARY
3.3.2 AUSTRIA
3.3.3 BELGIUM
3.3.4 BULGARIA
3.3.5 DENMARK
3.3.6 ESTONIA
3.3.7 FRANCE
3.3.8 GERMANY
3.3.9 GREECE
3.3.10 HUNGARY
3.3.11 IRELAND
3.3.12 ITALY
3.3.13 LUXEMBOURG
3.3.14 MALTA
3.3.15 SLOVENIA
3.3.16 SPAIN
3.3.17 SWEDEN
3.3.18 THE NETHERLANDS
3.3.19 THE UNITED KINGDOM
3.4 LATIN AMERICA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.4.1 EXECUTIVE SUMMARY
3.4.2 CHILE
3.4.3 COLOMBIA
3.4.4 HONDURAS
3.4.5 MEXICO
3.4.6 PANAMA
3.5 NORTH AMERICA & THE CARIBBEAN: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.5.1 EXECUTIVE SUMMARY
3.5.2 CANADA
3.5.3 THE UNITED STATES
3.6 OCEANIA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.6.1 EXECUTIVE SUMMARY
3.6.2 AUSTRALIA
3.6.3 NEW ZEALAND
3.7 THE MIDDLE EAST: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.7.1 EXECUTIVE SUMMARY
3.7.2 ISRAEL
3.7.3 PAKISTAN
3.7.4 SAUDI ARABIA
3.7.5 THE UNITED ARAB EMIRATES
3.7.6 TURKEY
4 IMPORTS
4.1 AFRICA: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.1.1 EXECUTIVE SUMMARY
4.1.2 ALGERIA
4.1.3 BENIN
4.1.4 BOTSWANA
4.1.5 EGYPT
4.1.6 ETHIOPIA
4.1.7 GUINEA
4.1.8 MADAGASCAR
4.1.9 MALAWI
4.1.10 MAURITANIA
4.1.11 MOROCCO
4.1.12 NAMIBIA
4.1.13 NIGERIA
4.1.14 SOUTH AFRICA
4.1.15 UGANDA
4.1.16 ZAMBIA
4.1.17 ZIMBABWE
4.2 ASIA: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.2.1 EXECUTIVE SUMMARY
4.2.2 BRUNEI
4.2.3 CHINA
4.2.4 INDIA
4.2.5 INDONESIA
4.2.6 JAPAN
4.2.7 MALAYSIA
4.2.8 NEPAL
4.2.9 SINGAPORE
4.2.10 SOUTH KOREA
4.2.11 TAIWAN
4.2.12 THAILAND
4.2.13 THE PHILIPPINES
4.2.14 VIETNAM
4.3 EUROPE: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.3.1 EXECUTIVE SUMMARY
4.3.2 AUSTRIA
4.3.3 BELARUS
4.3.4 BELGIUM
4.3.5 DENMARK
4.3.6 ESTONIA
4.3.7 FINLAND
4.3.8 FRANCE
4.3.9 GERMANY
4.3.10 GREECE
4.3.11 HUNGARY
4.3.12 IRELAND
4.3.13 ITALY
4.3.14 LITHUANIA
4.3.15 LUXEMBOURG
4.3.16 NORWAY
4.3.17 POLAND
4.3.18 PORTUGAL
4.3.19 RUSSIA
4.3.20 SLOVENIA
4.3.21 SPAIN
4.3.22 SWEDEN
4.3.23 THE NETHERLANDS
4.3.24 THE UNITED KINGDOM
4.3.25 UKRAINE
4.4 LATIN AMERICA: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.4.1 EXECUTIVE SUMMARY
4.4.2 ARGENTINA
4.4.3 BRAZIL
4.4.4 CHILE
4.4.5 COLOMBIA
4.4.6 EL SALVADOR
4.4.7 GUATEMALA
4.4.8 GUYANA
4.4.9 HONDURAS
4.4.10 MEXICO
4.4.11 NICARAGUA
4.4.12 PANAMA
4.4.13 PARAGUAY
4.4.14 PERU
4.4.15 URUGUAY
4.5 NORTH AMERICA & THE CARIBBEAN: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.5.1 EXECUTIVE SUMMARY
4.5.2 ARUBA
4.5.3 CANADA
4.5.4 GREENLAND
4.5.5 THE BAHAMAS
4.5.6 THE UNITED STATES
4.6 OCEANIA: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.6.1 EXECUTIVE SUMMARY
4.6.2 AUSTRALIA
4.6.3 FIJI
4.6.4 NEW ZEALAND
4.6.5 TONGA
4.7 THE MIDDLE EAST: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.7.1 EXECUTIVE SUMMARY
4.7.2 BAHRAIN
4.7.3 KUWAIT
4.7.4 OMAN
4.7.5 PAKISTAN
4.7.6 QATAR
4.7.7 TURKEY
4.7.8 YEMEN
5 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS
5.1 DISCLAIMERS & SAFE HARBOR
5.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS
1.1 OUR APPROACH
2 THE WORLD MARKET
2.1 EXPORTS
2.1.1 THE WORLD MARKET: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS EXPORT SUPPLIES IN 2024
2.2 IMPORTS
2.2.1 THE WORLD MARKET: IMPORTED MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3 EXPORTS
3.1 AFRICA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.1.1 EXECUTIVE SUMMARY
3.1.2 EGYPT
3.1.3 KENYA
3.1.4 MOROCCO
3.1.5 SOUTH AFRICA
3.2 ASIA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.2.1 EXECUTIVE SUMMARY
3.2.2 CHINA
3.2.3 INDIA
3.2.4 INDONESIA
3.2.5 JAPAN
3.2.6 MALAYSIA
3.2.7 SINGAPORE
3.2.8 SOUTH KOREA
3.2.9 TAIWAN
3.2.10 THAILAND
3.3 EUROPE: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.3.1 EXECUTIVE SUMMARY
3.3.2 AUSTRIA
3.3.3 BELGIUM
3.3.4 BULGARIA
3.3.5 DENMARK
3.3.6 ESTONIA
3.3.7 FRANCE
3.3.8 GERMANY
3.3.9 GREECE
3.3.10 HUNGARY
3.3.11 IRELAND
3.3.12 ITALY
3.3.13 LUXEMBOURG
3.3.14 MALTA
3.3.15 SLOVENIA
3.3.16 SPAIN
3.3.17 SWEDEN
3.3.18 THE NETHERLANDS
3.3.19 THE UNITED KINGDOM
3.4 LATIN AMERICA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.4.1 EXECUTIVE SUMMARY
3.4.2 CHILE
3.4.3 COLOMBIA
3.4.4 HONDURAS
3.4.5 MEXICO
3.4.6 PANAMA
3.5 NORTH AMERICA & THE CARIBBEAN: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.5.1 EXECUTIVE SUMMARY
3.5.2 CANADA
3.5.3 THE UNITED STATES
3.6 OCEANIA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.6.1 EXECUTIVE SUMMARY
3.6.2 AUSTRALIA
3.6.3 NEW ZEALAND
3.7 THE MIDDLE EAST: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IN 2024
3.7.1 EXECUTIVE SUMMARY
3.7.2 ISRAEL
3.7.3 PAKISTAN
3.7.4 SAUDI ARABIA
3.7.5 THE UNITED ARAB EMIRATES
3.7.6 TURKEY
4 IMPORTS
4.1 AFRICA: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.1.1 EXECUTIVE SUMMARY
4.1.2 ALGERIA
4.1.3 BENIN
4.1.4 BOTSWANA
4.1.5 EGYPT
4.1.6 ETHIOPIA
4.1.7 GUINEA
4.1.8 MADAGASCAR
4.1.9 MALAWI
4.1.10 MAURITANIA
4.1.11 MOROCCO
4.1.12 NAMIBIA
4.1.13 NIGERIA
4.1.14 SOUTH AFRICA
4.1.15 UGANDA
4.1.16 ZAMBIA
4.1.17 ZIMBABWE
4.2 ASIA: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.2.1 EXECUTIVE SUMMARY
4.2.2 BRUNEI
4.2.3 CHINA
4.2.4 INDIA
4.2.5 INDONESIA
4.2.6 JAPAN
4.2.7 MALAYSIA
4.2.8 NEPAL
4.2.9 SINGAPORE
4.2.10 SOUTH KOREA
4.2.11 TAIWAN
4.2.12 THAILAND
4.2.13 THE PHILIPPINES
4.2.14 VIETNAM
4.3 EUROPE: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.3.1 EXECUTIVE SUMMARY
4.3.2 AUSTRIA
4.3.3 BELARUS
4.3.4 BELGIUM
4.3.5 DENMARK
4.3.6 ESTONIA
4.3.7 FINLAND
4.3.8 FRANCE
4.3.9 GERMANY
4.3.10 GREECE
4.3.11 HUNGARY
4.3.12 IRELAND
4.3.13 ITALY
4.3.14 LITHUANIA
4.3.15 LUXEMBOURG
4.3.16 NORWAY
4.3.17 POLAND
4.3.18 PORTUGAL
4.3.19 RUSSIA
4.3.20 SLOVENIA
4.3.21 SPAIN
4.3.22 SWEDEN
4.3.23 THE NETHERLANDS
4.3.24 THE UNITED KINGDOM
4.3.25 UKRAINE
4.4 LATIN AMERICA: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.4.1 EXECUTIVE SUMMARY
4.4.2 ARGENTINA
4.4.3 BRAZIL
4.4.4 CHILE
4.4.5 COLOMBIA
4.4.6 EL SALVADOR
4.4.7 GUATEMALA
4.4.8 GUYANA
4.4.9 HONDURAS
4.4.10 MEXICO
4.4.11 NICARAGUA
4.4.12 PANAMA
4.4.13 PARAGUAY
4.4.14 PERU
4.4.15 URUGUAY
4.5 NORTH AMERICA & THE CARIBBEAN: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.5.1 EXECUTIVE SUMMARY
4.5.2 ARUBA
4.5.3 CANADA
4.5.4 GREENLAND
4.5.5 THE BAHAMAS
4.5.6 THE UNITED STATES
4.6 OCEANIA: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.6.1 EXECUTIVE SUMMARY
4.6.2 AUSTRALIA
4.6.3 FIJI
4.6.4 NEW ZEALAND
4.6.5 TONGA
4.7 THE MIDDLE EAST: MEDICAMENTS CONTAINING PENICILLINS, STREPTOMYCINS, OR THEIR DERIVATIVES EXCLUDING THOSE IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024
4.7.1 EXECUTIVE SUMMARY
4.7.2 BAHRAIN
4.7.3 KUWAIT
4.7.4 OMAN
4.7.5 PAKISTAN
4.7.6 QATAR
4.7.7 TURKEY
4.7.8 YEMEN
5 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS
5.1 DISCLAIMERS & SAFE HARBOR
5.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS
